Daiwa Securities Group
RNAC icon

Daiwa Securities Group’s Cartesian Therapeutics RNAC Stock Holding History

Daiwa Securities Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-84
Closed -$1K – 1427
2025
Q3 		$1K Hold
84
– – ﹤0.01% 1320
2025
Q2 		$1K Hold
84
– – ﹤0.01% 1282
2025
Q1 		$1K Hold
84
– – ﹤0.01% 1249
2024
Q4 		$2K Buy
+84
New +$1.7K ﹤0.01% 1229
2023
Q4 		– Sell
-7
Closed – – 1381
2023
Q3 		$0 Hold
7
– – ﹤0.01% 1330
2023
Q2 		$0 Hold
7
– – ﹤0.01% 1346
2023
Q1 		$0 Hold
7
– – ﹤0.01% 1316
2022
Q4 		$0 Hold
7
– – ﹤0.01% 1375
2022
Q3 		$0 Hold
7
– – ﹤0.01% 1385
2022
Q2 		$0 Hold
7
– – ﹤0.01% 1415
2022
Q1 		$0 Hold
7
– – ﹤0.01% 1409
2021
Q4 		$1K Hold
7
– – ﹤0.01% 1357
2021
Q3 		$1K Hold
7
– – ﹤0.01% 1281
2021
Q2 		$1K Hold
7
– – ﹤0.01% 1209
2021
Q1 		$1K Hold
7
– – ﹤0.01% 1220
2020
Q4 		$1K Buy
+7
New +$607 ﹤0.01% 1200

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Daiwa Securities Group's RNAC Position: Q4 2025 in Review

Daiwa Securities Group sold out of Cartesian Therapeutics (RNAC) in Q4 2025, closing a stake of 84 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in RNAC in Q4 2020 and held it in 16 quarters. The position peaked at $2K in Q4 2024. 67 funds tracked by Wall St. Rank hold RNAC as of Q4 2025.

  • Daiwa Securities Group reported no remaining Cartesian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Daiwa Securities Group sold 84 Cartesian Therapeutics shares in Q4 2025, an estimated $1K.
  • Daiwa Securities Group first reported a position in Cartesian Therapeutics in Q4 2020 and held it in 16 quarters.
  • Daiwa Securities Group's Cartesian Therapeutics position peaked at $2K in Q4 2024.
  • 67 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2025.

Based on Daiwa Securities Group's 13F filing for Q4 2025, filed 11 Feb 2026.